InSilico Medicine Cayman TopCo stock
Price history
−18.57% over the periodFull history: from $37.58 (January 2, 2026) to $30.60 (November 20, 2026), −18.57%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $30.60 |
| October 30, 2026 | $36.00 |
| September 25, 2026 | $55.65 |
| August 28, 2026 | $46.30 |
| July 31, 2026 | $45.70 |
| June 26, 2026 | $38.22 |
| May 29, 2026 | $41.58 |
| April 30, 2026 | $63.05 |
| March 27, 2026 | $57.20 |
| February 27, 2026 | $61.95 |
| January 30, 2026 | $62.90 |
| January 2, 2026 | $37.58 |
At a glance
The company
Applies artificial intelligence to drug discovery and development using its proprietary Pharma.AI platform
Latest results
Quarter to June 30, 2026 · EPS $0.06
TickerLandia's take on InSilico Medicine Cayman TopCo
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−62.18% from the 52-week high
Analysts · 12 analysts
Average target$76.70+150.65% vs. price
Buy 12 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: InSilico Medicine Cayman TopCo
Compared with similar companies: very high risk and very weak momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Priceaverage57
How much it costs relative to what it produces.
Metric Value Position in group Price/book 4.64 41 Forward P/E 19.9 38 Price/sales 150.3 94 Profitabilityaverage46
How much it earns on revenue and capital.
Metric Value Position in group ROE 443.1% 99 ROA −1.4% 30 Operating margin −6.9% 29 Net marginabove 100%: likely one-off items −220.3% 1 Gross margin 87.9% 70 Earnings stabilitylow33
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 94.3% 35 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthaverage52
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −124.00% 12 Revenue growth (year over year) +287.20% 94 Average revenue growth (3 years) +23.10% 52 Financial strengthaverage53
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −287.0 3 Current ratio 8.71 86 Debt/equitycounts in reverse: lower means more financial strength 0.04 69 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak14
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −20.61% 17 Relative strength (6 months) −27.27% 15 Distance from 200-day average −39.20% 11 Riskvery high86
How much the price swings.
Metric Value Position in group Beta (1 year) 1.64 84 Volatility (60 days) 76.5% 90 Maximum drawdown (12 months) 60.2% 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
InSilico Medicine Cayman TopCo is cheaper than similar companies
InSilico Medicine Cayman TopCo's Forward P/E: 19.9, −45% against the median of a group of 9 similar companies (36.1).
Compared with 9 similar companies
| Metric | InSilico Medicine Cayman TopCo | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 19.9 | Low | |
| Operating margin | -6.9% | Middle | |
| ROE | 443.1% | High | |
| Debt/equity | 0.04 | Low | |
| Price/book | 4.64 | Middle |
Grey band: the middle half of the group; tick: the median; dot: InSilico Medicine Cayman TopCo. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$106.3M
Latest quarter · Q2 2026
Net income
$35.54M
Latest quarter · Q2 2026
Quarterly net margin
33.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $20.31B
- EPS
- -$34.26
- Volume
- 6.15M
- Daily trading
- €42.69M
- Dividend yield
- 0.00%
How InSilico Medicine Cayman TopCo is changing
All resultsRevenue grew 23.1% a year on average over the last 3 years
Operating margin rose from −265.8% to −106.7%
Shares outstanding up 17.4% in 3 years
Returns
InSilico Medicine Cayman TopCo returns
| Period | InSilico Medicine Cayman TopCo | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −22.41% | −6.10% | $776 |
| 6 months | −36.46% | −12.63% | $635 |
| Year to date | −17.79% | −12.56% | $822 |
Over the last 6 months it has done better than 6% of the stocks in the Healthcare sector.
Price only, without dividends.
The chart in detail
InSilico Medicine Cayman TopCo: technical analysis
InSilico Medicine Cayman TopCo is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 60.2% below its all-time closing high ($76.85, February 16, 2026).
- Trend
- Downward
- RSI (14 sessions)
- 29
- Below 30: a strong fall in a short time
- vs 200-session average
- −39.20%
Active signals
Close below the low of the previous 55 sessions.
RSI below 30: the stock has fallen a lot in a short time.
Support and resistance
Price areas where InSilico Medicine Cayman TopCo has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$41.18+34.58%2 touches, last on November 12, 2026
- Resistance$39.15+27.93%3 touches, last on August 19, 2026
- Resistance$34.04+11.24%2 touches, last on October 23, 2026
- Last price$30.60
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.64
- Volatility (60 sessions, annualised)
- 76.5%
- Largest fall in the last year
- −60.18%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
InSilico Medicine Cayman TopCo and its competitors
Employing 333 people, InSilico Medicine Cayman TopCo applies artificial intelligence to drug discovery and development through its proprietary Pharma.AI platform, which offers target identification, small molecule generation and clinical outcome prediction. Its pipeline covers fibrosis, oncology, immunology, metabolic and anti-pain programs, and its work runs through research and development collaborations with partners including Takeda and Servier, as well as a strategic agreement with Suzhou Ribo Life Science on oligonucleotide therapeutics.
- Headquarters
- Hong Kong, Hong Kong
- Employees
- 333
- Founded
- 2014
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| InSilico Medicine Cayman TopCo3696 | $2.59B | -6.9% | — | −36.46% |
| Telix PharmaceuticalsTLX | $2.92B | 6.2% | 92.3 | −7.71% |
| Neuren PharmaceuticalsNEU | $1.83B | 19.9% | 144.0 | +68.84% |
| MesoblastMSB | $1.48B | -42.6% | — | −14.82% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
| Metis TechBio7666 | $1.11B | -131.2% | — | −63.08% |
Same industry or related industries, similar size. Compare InSilico Medicine Cayman TopCo with its competitors · Full profile
